Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer

Prostate Carcinoma Clinical Trial

— MSG PSMA PET  

Official title:

Evaluation by 68Ga-PSMA-11 PET Imaging of Monosodium Glutamate as a Potential Agent for Salivary Gland Protection Under PSMA-targeted Alpha-therapy: a Randomized Pilot Imaging Research Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04282824
• Other study ID #: 18-001776
• Secondary ID: NCI-2019-0443718
• Status: Completed
• Phase: Early Phase 1
• Start date: June 5, 2019
• Est. completion date: May 6, 2020

Study information

• Verified date: November 2020
• Source: Jonsson Comprehensive Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase I trial studies the impact of monosodium glutamate (MSG) on 68GA-PSMA-11 PET/CT in decreasing the salivary glands uptake in patients with prostate cancer. Prostate specific membrane antigen (PSMA) is a molecule that is overexpressed by the prostate cancer cells. 68GA-PSMA-11 is an imaging radioactive drug that can target this molecule in tissues for imaging and therapy of prostate cancer. Food substances, such as monosodium glutamate, may reduce salivary gland uptake of 68GA-PSMA-11. Ultimately, giving MSG may reduce potential harm and injury to the salivary glands in patients with prostate cancer treated with PSMA-targeted molecular radiotherapy.

Description:

PRIMARY OBJECTIVE: I. To determine the effect of monosodium glutamate (MSG) administration (glutamate supplementation) on the salivary gland uptake of gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11). SECONDARY OBJECTIVES: I. To determine the effect of MSG administration on renal 68Ga-PSMA-11 uptake. II. To determine the effect of MSG administration on tumor 68Ga-PSMA-11 uptake. III. To determine if 68GA-PSMA-11 is excreted in the saliva. IV. Safety of MSG administration both oral ingestion and oral-salivary stimulation. OUTLINE: Patients are randomized to 1 of 2 arms. Arm I: Patients receive gallium Ga 68-labeled PSMA-11 intravenously (IV) and undergo a positron emission tomography (PET)/computed tomography (CT) scan on day 1. Within 2 weeks (days 2-14), patients receive MSG orally (PO) over 10 minutes and receive a second dose of gallium Ga 68-labeled PSMA-11 IV, followed by a second PET/CT scan. Patients also undergo collection of saliva at 0, 30, and 60 minutes after gallium Ga 68-labeled PSMA-11 injection and 90 minutes after PET/CT. Arm II: Patients receive gallium Ga 68-labeled PSMA-11 IV and undergo a PET/CT scan on day 1. Within 2 weeks (days 2-14), patients receive a second dose of gallium Ga 68-labeled PSMA-11 IV immediately followed by MSG applied in the mouth over 30 seconds every 10 minutes for a total of 6 times, and then undergo a second PET/CT scan. Patients also undergo collection of saliva at 0, 30, and 60 minutes after gallium Ga 68-labeled PSMA-11 injection and 90 minutes after PET/CT.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 14
• Est. completion date: May 6, 2020
• Est. primary completion date: May 6, 2020
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient volunteer to undergo 2 PSMA PET/CT scans within 14 days
• Histopathologically proven prostate cancer (PCa)
• PSMA PET/CT indicated for :
• Initial staging before definitive therapy
• Biochemical recurrence localization
• Metastatic disease re-staging
• Ability to understand a written informed consent document and the willingness to sign it
• Ability to ingest 300 mL of fluid across 10 minute period

Exclusion Criteria:

• Prior salivary gland surgery or radiation therapy
• Prior history or current salivary gland disease
• Unable to lie flat, still or tolerate a PET scan
• Unable to follow the salivary flow stimuli administration regimen
• Unable to follow the glutamate supplementation administration regimens
• Asthma
• Severe uncontrolled hypertension (systolic blood pressure above 140 mm Hg and diastolic blood pressure above 90 mm Hg, or systolic blood pressure above 180 mm Hg, or diastolic blood pressure above 110 mg Hg). Patients with controlled hypertension under medication are eligible
• Sodium/salt restricted diet due to other medical conditions
• History of severe asthma that has led to hospitalizations or emergency room visits
• History of severe contraindications to MSG consumption including severe headaches, migraines or other intolerance
• Change to treatment administered between time of baseline scan and MSG scan

Related Conditions & MeSH terms

• Prostate Carcinoma
• Prostatic Neoplasms

Intervention

Procedure:
• Biospecimen Collection
Undergo collection of saliva
• Computed Tomography
Undergo PET/CT

Drug:
• Gallium Ga 68-labeled PSMA-11
Given IV

Dietary Supplement:
• Monosodium Glutamate
Given PO

Procedure:
• Positron Emission Tomography
Undergo PET/CT

Locations

Country	Name	City	State
United States	UCLA / Jonsson Comprehensive Cancer Center	Los Angeles	California

Sponsors (1)

Lead Sponsor	Collaborator
Jonsson Comprehensive Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Salivary gland uptake of gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11)	Standard uptakes values (SUV) values (maximum SUV [SUVmax] and SUVmean) in all assessable salivary glands will be measured with a spherical volume-of-interest with and without the administration of monosodium glutamate (MSG) interventions. SUVmax/salivary gland will be calculated and a mean SUVmax/patient will be generated. The aim is to show a 2-fold reduction of the salivary gland 68Ga-PSMA-11 uptake after MSG administration. Paired T-test will be used to determine statistical significance per salivary gland and per patient.	2 measurements within 2 to 14 days maximum (on positron emission tomography [PET]1 and PET2)
Secondary	Renal 68Ga-PSMA-11 uptake	SUVmax and SUVmean in the kidneys will be measured with a spherical volume-of-interest with and without the administration of MSG interventions. SUVmax/kidneys will be calculated and a mean SUVmax/patient will be generated. Paired T-test will be used to determine statistical significance per salivary gland and per patient.	2 measurements within 2 to 14 days maximum (on PET1 and PET2)
Secondary	Tumor 68Ga-PSMA-11 uptake	SUVmax and SUVmean in the visible tumor lesions will be measured with a spherical volume-of-interest with and without the administration of MSG interventions. SUVmax/tumor lesions will be calculated and a mean SUVmax/patient will be generated. Paired T-test will be used to determine statistical significance per salivary gland and per patient.	2 measurements within 2 to 14 days maximum (on PET1 and PET2)
Secondary	Saliva radioactivity concentration	Saliva radioactivity concentration will be compared with and without saliva stimuli.	2 measurements within 2 to 14 days maximum (on PET1 and PET2)
Secondary	Incidence of adverse events of MSG administration		Up to 6 months